ArticleFrontiers in immunology2022

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy.

Linfang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.